Compare Wipro Limited (WIT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wipro Limited vs Zimmer Biomet Holdings Inc — how do they compare? Wipro Limited trades at $1.71 (market cap $16.22B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Wipro Limited and Zimmer Biomet Holdings Inc are close in size by market cap, and Wipro Limited pays the higher dividend (5.19%). Which is the better fit depends on your goals — on Pluang, investors hold Wipro Limited for 41 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| WIT | ZBH | |
|---|---|---|
Market Cap | $16.22B | $16.95B |
Volume | 9,028,667 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $3.06 | $103.98 |
52-Week Low | $1.61 | $79.58 |
Typical Hold Time | 41 Days | 89 Days |
Enterprise Value | $14.33B | $24.02B |
Dividend Yield | 5.19% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WIT trades at $1.715, up 2.69% today, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with recent earnings misses but maintains solid profitability and cash flow. Recent news highlights AI-driven productivity gains and strategic partnerships, though revenue growth remains subdued. Analyst sentiment is cautious with a majority hold rating.
The outlook is balanced: valuation appears reasonable with a P/E of 12.78, and strong cash flow supports stability. However, earnings misses and bearish technicals pose near-term risks. Investment appeal hinges on execution of AI initiatives and revenue acceleration against competitive pressures.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
